MXPA05008109A - Derivados de urea y tiourea. - Google Patents

Derivados de urea y tiourea.

Info

Publication number
MXPA05008109A
MXPA05008109A MXPA05008109A MXPA05008109A MXPA05008109A MX PA05008109 A MXPA05008109 A MX PA05008109A MX PA05008109 A MXPA05008109 A MX PA05008109A MX PA05008109 A MXPA05008109 A MX PA05008109A MX PA05008109 A MXPA05008109 A MX PA05008109A
Authority
MX
Mexico
Prior art keywords
urea
thiourea derivatives
moet
zene
exc
Prior art date
Application number
MXPA05008109A
Other languages
English (en)
Inventor
Yunlong Du Daniel
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA05008109A publication Critical patent/MXPA05008109A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/14Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invencion se dirige a una nueva clase de compuestos quinolin-zeno y z-exc cromeno que han sido derivatizados en la posicion 6 con una urea o este resto de urea, y su uso como agentes antagonistas de los androgenos.
MXPA05008109A 2003-02-11 2004-01-30 Derivados de urea y tiourea. MXPA05008109A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44640903P 2003-02-11 2003-02-11
PCT/IB2004/000295 WO2004072044A2 (en) 2003-02-11 2004-01-30 Urea and thiourea derivatives

Publications (1)

Publication Number Publication Date
MXPA05008109A true MXPA05008109A (es) 2005-09-21

Family

ID=32869502

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008109A MXPA05008109A (es) 2003-02-11 2004-01-30 Derivados de urea y tiourea.

Country Status (7)

Country Link
US (1) US7074933B2 (es)
EP (1) EP1603882A2 (es)
JP (1) JP2006517578A (es)
BR (1) BRPI0407354A (es)
CA (1) CA2515589A1 (es)
MX (1) MXPA05008109A (es)
WO (1) WO2004072044A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540327A (ja) * 2004-09-02 2008-11-20 シー.ワイ. シー,チャールズ 核内受容体転写因子の分解を増強するための方法及び組成物並びにその使用
GB0720061D0 (en) * 2007-10-13 2007-11-21 Finnen Michael Method & composition for the treatment of acne and sebum dependent pilosebaceous disorders
CN108148034B (zh) * 2018-01-12 2021-06-01 青岛农业大学 一类含氟取代脲基香豆素衍生物及其除草与杀菌用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5811947B2 (ja) * 1976-12-10 1983-03-05 大塚製薬株式会社 カルボスチリル誘導体
JPS58102936A (ja) * 1981-12-15 1983-06-18 Konishiroku Photo Ind Co Ltd ハロゲン化銀カラ−写真感光材料
JPS59164554A (ja) * 1983-03-08 1984-09-17 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
US6017924A (en) * 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1212322A2 (en) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
JP2003508402A (ja) 1999-08-27 2003-03-04 リガンド・ファーマシューティカルズ・インコーポレイテッド アンドロゲン受容体モジュレーター化合物および方法

Also Published As

Publication number Publication date
US7074933B2 (en) 2006-07-11
CA2515589A1 (en) 2004-08-26
JP2006517578A (ja) 2006-07-27
WO2004072044A2 (en) 2004-08-26
BRPI0407354A (pt) 2006-01-10
US20040266820A1 (en) 2004-12-30
WO2004072044A3 (en) 2004-11-11
EP1603882A2 (en) 2005-12-14

Similar Documents

Publication Publication Date Title
IL176571A0 (en) Substituted azole derivatives, compositions, and methods of use
EP1626717A4 (en) BENZIMIDAZOLE, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
HK1115752A1 (en) Benzazole derivatives, compositions, and methods of use as
ECSP12007067A (es) Derivados de quinazolinona útiles como antagonistas vanilloides
HN2003000285A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
TW200716525A (en) Process for preparation of sulfamide derivatives
MXPA03006363A (es) Derivados de urea como antagonistas de integrinas alfa-4.
IL174215A0 (en) Benzimidazole derivatives, compositions containing them preparation thereof and uses thereof
UA92730C2 (ru) Аналоги бензазола и их применение
IL172023A0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
IL172027A0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
UY28917A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas composiciones farmaceuticas y su uso terapeutico
DE60321722D1 (de) Derivate von aryl-chinazolin/aryl-2amino-phenyl-methanon zurförderung der freisetzung von parathormon
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
MXPA03010158A (es) Sulfonamidas.
MXPA05007605A (es) Antagonista del receptor de androgenos.
PL1898901T3 (pl) Stabilne postacie dawkowania spiro i dispiro 1, 2, 4-trioksolanowych związków przeciwmalarycznych
DE602005010453D1 (de) Antibakterielle zusammensetzung
MXPA05009988A (es) Derivados de 6-sulfonamida quinolina y cromeno como antagonistas de los receptores de androgenos.
PT1638943E (pt) Novos derivados de imidazoles, sua preparação e sua utilização como medicamento
MXPA05008109A (es) Derivados de urea y tiourea.
SI1532141T1 (sl) 2-pirolidin-2-il-(1,3,4)-oksadiazolni derivati in njihova uporaba kot antidepresivi
BR0208221A (pt) Combinação de uma taxano e uma cinase dependente de ciclina
IL165942A0 (en) Acyloxypyrrolidine derivatives and use thereof as ligands of vib or both vib and via receptors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal